2020
DOI: 10.14309/ctg.0000000000000156
|View full text |Cite
|
Sign up to set email alerts
|

Diagnosis and Treatment of Duodenal Gastrointestinal Stromal Tumors

Abstract: OBJECTIVES: The diagnostic value of different noninvasive diagnostic modalities and the endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) reliability of duodenal gastrointestinal stromal tumors (GISTs) are ambiguous in the present studies. METHODS: Patients with a histopathological diagnosis of the primary duodenal GISTs between the years 2008 and 2018 were analyzed. Data on the treatment and clinicopathological features were recorded. Furth… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0
4

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(12 citation statements)
references
References 27 publications
0
8
0
4
Order By: Relevance
“…The diagnosis of DGIST was confirmed by immunohistochemical staining. Inclusion criteria are as follows: (1) Patients who underwent laparotomy; (2) Patients with DGISTs, as proven by pathology or immunohistochemistry (CD117, CD34, DOG1 and Ki67); (3) The tumor was located in the duodenum, as confirmed by preoperative abdominal computed tomography scan, ultrasound, endoscopy, upper gastrointestinal barium swallow, and surgery; and (4) Patients with GIST synchronous with other malignancies were excluded[ 7 ]. The risk grade of DGIST was assessed by a pathologist.…”
Section: Methodsmentioning
confidence: 99%
“…The diagnosis of DGIST was confirmed by immunohistochemical staining. Inclusion criteria are as follows: (1) Patients who underwent laparotomy; (2) Patients with DGISTs, as proven by pathology or immunohistochemistry (CD117, CD34, DOG1 and Ki67); (3) The tumor was located in the duodenum, as confirmed by preoperative abdominal computed tomography scan, ultrasound, endoscopy, upper gastrointestinal barium swallow, and surgery; and (4) Patients with GIST synchronous with other malignancies were excluded[ 7 ]. The risk grade of DGIST was assessed by a pathologist.…”
Section: Methodsmentioning
confidence: 99%
“…All GISTs have malignant potential, which appears to be higher in those arising in the small intestine comparing to the gastric ones [8] , [9] . Histologically, the best known prognostic factors are tumour size and the mitotic index.…”
Section: Discussionmentioning
confidence: 99%
“…Tumors which are ≤2 cm in diameter with ≤5 mitoses per 50 high power fields are usually benign with good prognosis. GIST which are >5 cm or >5mitoses per 50 high power fields are likely to be malignant; and poor prognostic factors include tumour necrosis, extensive hemorrhage unrelated to surgery, hypercellularity, marked cellular atypia and epithelioid pattern with mucosal invasion [8] , [9] . About 30–50% of the GIST are malignant with 5 year survival of 50%; malignant tumors usually metastasize to liver and peritoneum [9] .…”
Section: Discussionmentioning
confidence: 99%
“…Большинство ГИСО спорадические, однако в 5% наблюдений их выявляют у пациентов с нейрофиброматозом I типа (НФ-1) и триадой Карнея [15]. Кли ническая картина неспецифична: симптомы желудочно-кишеч ного кровотечения (44,4%), следующие за абдоминальной болью и метеориз-мом (27,5%) [16]. В ДПК ГИСО чаще локализуются в сегментах D2 (52,1%) и D1 (19%) [16].…”
Section: обсуждение результатовunclassified